Athira Pharma Inc

NASDAQ:ATHA  
2.74
-0.01 (-0.36%)
Regulatory, Earnings Announcements

Athira Pharma Reports Results From Phase 2 Study Of Alzheimer's Disease Treatment

Published: 06/22/2022 11:26 GMT
Athira Pharma Inc (ATHA) - Athira Pharma Announces Topline Results From Act-ad Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-moderate Alzheimer’s Disease.
Athira Pharma Inc - Primary Endpoint of Change in Biomarker Erp P300 Latency Was Not Statistically Significant for Full Study Population.
Athira Pharma Inc - Combination of Fosgonimeton and Standard-of-care (acheis) Given Together Showed Potential Diminished Effect of Fosgonimeton.
Athira Pharma Inc - Fosgonimeton Had a Favorable Safety Profile Over 26 Weeks and Act-ad Provides Important Learnings for Ongoing Lift-ad Study.
Athira Pharma Inc - a Pre-specified Subgroup Analysis of Patients on Fosgonimeton Monotherapy Suggests Improvement in Erp P300 Latency at Week 26.
Athira Pharma Inc - a Pre-specified Subgroup Analysis of Patients on Fosgonimeton Monotherapy Suggests Improvement in Adas-cog11 at Week 26.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.64

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.70

More details on our Analysts Page.